Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics • Exelixis ...
Former names
AMGEN
SEC CIK
Corporate docs
Subsidiaries
Amgen (Europe) GmbH • Amgen Canada Inc. • Amgen Fremont Inc. • Amgen Global Finance B.V. • Amgen GmbH • Amgen Ilaç Ticaret Limited • Amgen K-A, Inc. • Amgen Manufacturing, Limited • Amgen Research (Munich) GmbH • Amgen S.A.S. ...
IRS number
953540776
AMGN stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Amgen Reports Third Quarter Financial Results
31 Oct 23
S-8
Registration of securities for employees
6 Oct 23
8-K
Amgen Completes Acquisition of Horizon Therapeutics PLC
6 Oct 23
8-K
Other Events
5 Oct 23
8-K
Other Events
12 Sep 23
8-K
Other Events
5 Sep 23
8-K
Regulation FD Disclosure
1 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Departure of Directors or Certain Officers
3 Aug 23
Transcripts
AMGN
Earnings call transcript
2023 Q3
31 Oct 23
AMGN
Earnings call transcript
2023 Q2
3 Aug 23
AMGN
Earnings call transcript
2023 Q1
27 Apr 23
AMGN
Earnings call transcript
2022 Q4
31 Jan 23
AMGN
Earnings call transcript
2022 Q3
4 Nov 22
AMGN
Earnings call transcript
2022 Q2
5 Aug 22
AMGN
Earnings call transcript
2022 Q1
28 Apr 22
AMGN
Earnings call transcript
2021 Q3
3 Nov 21
AMGN
Earnings call transcript
2021 Q2
4 Aug 21
AMGN
Earnings call transcript
2021 Q1
28 Apr 21
Latest ownership filings
4
Nancy A. Grygiel
4 Dec 23
144
Notice of proposed sale of securities
4 Dec 23
4
DAVID M REESE
29 Nov 23
4
Jonathan P Graham
13 Nov 23
144
Notice of proposed sale of securities
8 Nov 23
4
Derek Miller
7 Nov 23
4
Rachna Khosla
7 Nov 23
4
Nancy A. Grygiel
7 Nov 23
4
Matthew C. Busch
7 Nov 23
4
OMAR ISHRAK
7 Nov 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2023
74.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2422 |
| Opened positions | 290 |
| Closed positions | 146 |
| Increased positions | 926 |
| Reduced positions | 863 |
| 13F shares | Current |
|---|---|
| Total value | 106.95 tn |
| Total shares | 398.07 mm |
| Total puts | 5.55 mm |
| Total calls | 4.90 mm |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 49.04 mm | $13.18 tn |
| BLK Blackrock | 47.57 mm | $12.79 tn |
| STT State Street | 28.58 mm | $7.68 tn |
| Primecap Management | 14.73 mm | $3.96 tn |
| MS Morgan Stanley | 13.25 mm | $3.56 tn |
| Geode Capital Management | 12.14 mm | $3.26 tn |
| Charles Schwab Investment Management | 10.89 mm | $2.93 tn |
| Capital Research Global Investors | 8.49 mm | $2.28 tn |
| WFC Wells Fargo & Co. | 7.58 mm | $2.04 tn |
| NTRS Northern Trust | 6.98 mm | $1.88 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Dec 23 | Nancy A. Grygiel | Common Stock | Sell | Dispose S | No | No | 273.0323 | 2,096 | 572.28 k | 10,874 |
| 28 Nov 23 | David M Reese | Common Stock | Gift | Dispose G | No | No | 0 | 165 | 0.00 | 54,164 |
| 8 Nov 23 | Jonathan P Graham | Common Stock | Sell | Dispose S | No | No | 272.8136 | 10,000 | 2.73 mm | 28,078 |
| 5 Nov 23 | Matthew C. Busch | Common Stock | Payment of exercise | Dispose F | No | No | 269.86 | 183 | 49.38 k | 4,367 |
| 5 Nov 23 | Matthew C. Busch | Common Stock | Payment of exercise | Dispose F | No | No | 269.86 | 66 | 17.81 k | 4,550 |
| 5 Nov 23 | Nancy A. Grygiel | Common Stock | Payment of exercise | Dispose F | No | No | 269.86 | 249 | 67.20 k | 12,970 |
News
Press releases
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
8 Dec 23
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
22 Nov 23
1 in 25 carries a genotype that is associated with a shortened lifespan
15 Nov 23
Biosimilars Market Expected to Witness Massive Growth with a Tremendous CAGR of 21.54%, asserts DelveInsight | Companies – Pfizer Inc., Dr. Reddy's Laboratories Ltd., Amgen, Eli Lilly and Company
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
8 Nov 23